Market Place
Sourcing Support
EnteroBiotix Completes EBX-102-02 Study Recruitment in IBS
18 Nov 2024 //
GLOBENEWSWIRE
EnteroBiotix Completes Ph 2 Study Recruitment of EBX-102-02 in IBS
18 Nov 2024 //
GLOBENEWSWIRE
EnteroBiotix Announces Positive EBX-102 Results in Liver Cirrhosis
11 Nov 2024 //
GLOBENEWSWIRE
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
04 Apr 2024 //
GLOBENEWSWIRE
EnteroBiotix Initiates Phase 2 Study of EBX-102-02 in Patients with IBS
03 Apr 2024 //
GLOBENEWSWIRE
EnteroBiotix Strengthens its Executive Team, Appoints COO and CFO
01 Feb 2024 //
GLOBENEWSWIRE
EnteroBiotix appoints Elmar Schnee as Executive Chairman
17 Jul 2023 //
GLOBENEWSWIRE
EnteroBiotix Initiates Phase 2 study of microbiome drug EBX-102
28 Mar 2023 //
GLOBENEWSWIRE
EnteroBiotix announces partnership with Imperial College London
11 Nov 2022 //
PHARMATIMES
EnteroBiotix partners with Imperial College London to develop microbiome
10 Nov 2022 //
PRNEWSWIRE
EnteroBiotix receives MHRA MIA (IMP) licensure of state-of-the-art GMP MFG
11 Oct 2022 //
PHARMIWEB
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.